{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-202307","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.208001+00:00","generated_at":"2026-05-17T06:44:30.898696+00:00","sec_items":["1.01","8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alkermes sues Teva, Apotex, MSN over LYBALVI patents; enters VIVITROL AG deal with Amneal","bullets":["Filed patent lawsuits against Teva (8/15), Apotex (8/27), MSN (9/5) over generic LYBALVI; 30-month FDA stays triggered.","LYBALVI patents expiring 2032-2041; lawsuit amended 8/20 to include additional patent.","Entered authorized generic supply agreement with Amneal for VIVITROL, effective upon third-party ANDA launch.","Amneal may distribute AG VIVITROL for one year, supply limited to ~15% of 2024 unit sales; profit sharing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-202307","json":"https://secwatch.observer/filing/0001193125-25-202307.json","markdown":"https://secwatch.observer/filing/0001193125-25-202307.md","text":"https://secwatch.observer/filing/0001193125-25-202307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525202307/0001193125-25-202307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000119312525202307/alks-20250815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:44:30.898696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}